Oxford Nanopore Technologies reported preliminary H1 2025 revenues of approximately £105 million, representing a 25% year-over-year increase driven by strong growth in research and applied markets including biopharma and clinical diagnostics. Expansion was particularly notable in EMEAI and Asia Pacific regions. PromethIon platform sales rose 59% annually. Despite challenges in the US research environment, the company is progressing toward profitability, supported by disciplined cost management and increased gross profit. Full H1 financial results are due September 2.